Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
33 hedge funds and large institutions have $70M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
29% less capital invested
Capital invested by funds: $98.3M → $70M (-$28.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.64M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.36M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$321K |
| 4 |
CCMU
Cheyne Capital Management (UK)
London,
United Kingdom
|
+$301K |
| 5 |
Barclays
London,
United Kingdom
|
+$145K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$9.31M |
| 2 |
Morgan Stanley
New York
|
-$603K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$302K |
| 4 |
CII
Capital International Inc
Los Angeles,
California
|
-$225K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$79.5K |
GRCL Hedge Fund Activity: Q4 2022 in Review
33 institutional investors reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q4 2022, worth a combined $70M — down 29% from $98.3M a quarter earlier.
Fund positioning in GRCL was balanced in Q4 2022: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 12 trimmed.
The largest buyer was Great Point Partners, adding an estimated $4.64M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $9.31M sold.
- 33 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $70M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q4 2022, down 29% quarter-over-quarter.
- 3 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q4 2022 and 3 closed out, a net change of 0 holders.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q4 2022 was Great Point Partners, an estimated $4.64M added.
- The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q4 2022 was Frazier Life Sciences Management, an estimated $9.31M sold.
Based on aggregated 13F filings for Q4 2022.